Characteristics of 101 Alberta patients for whom RHAMM ratio determination was assessed in bone marrow samples taken at the time of diagnosis
Factor . | Prevalence, no. patients/total no. (%) . |
|---|---|
| Age, 65 y or older | 63/101 (63) |
| Female | 35/101 (35) |
| Kappa | 58/95 (61) |
| Lambda | 34/95 (36) |
| IgA isotype | 19/97 (20) |
| β2M, 4 mg/L (340 nM) or higher | 41/74 (55) |
| Creatinine, 2 mg/dL (176.8 μM) or higher | 19/100 (19) |
| LDH elevated | 13/75 (26) |
| Albumin below 35 g/L | 44/98 (45) |
| Hypercalcemia | 7/97 (7) |
| HGB below 100 g/L | 40/100 (40) |
| BMPC, 33% or higher | 54/98 (55) |
| 1 or more x-ray focal lesions | 72/101 (71) |
| 3 or more x-ray focal lesions | 59/101 (58) |
| High-dose chemotherapy | 30/101 (30) |
Factor . | Prevalence, no. patients/total no. (%) . |
|---|---|
| Age, 65 y or older | 63/101 (63) |
| Female | 35/101 (35) |
| Kappa | 58/95 (61) |
| Lambda | 34/95 (36) |
| IgA isotype | 19/97 (20) |
| β2M, 4 mg/L (340 nM) or higher | 41/74 (55) |
| Creatinine, 2 mg/dL (176.8 μM) or higher | 19/100 (19) |
| LDH elevated | 13/75 (26) |
| Albumin below 35 g/L | 44/98 (45) |
| Hypercalcemia | 7/97 (7) |
| HGB below 100 g/L | 40/100 (40) |
| BMPC, 33% or higher | 54/98 (55) |
| 1 or more x-ray focal lesions | 72/101 (71) |
| 3 or more x-ray focal lesions | 59/101 (58) |
| High-dose chemotherapy | 30/101 (30) |
RHAMM ratios did not significantly correlate with any of the parameters listed.